MDGL PE Ratio & Valuation, Is MDGL Overvalued

Historical Valuation

Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.90 is considered Undervalued compared with the five-year average of 17.24. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 14472.03 to 14601.33 according to relative valuation method. Compared to the current price of 444.83 USD , Madrigal Pharmaceuticals Inc By Undervalued By 96.93%.

Relative Value

Fair Zone

14472.03-14601.33

Current Price：444.83

96.93%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Madrigal Pharmaceuticals Inc (MDGL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Madrigal Pharmaceuticals Inc (MDGL) has a current Price-to-Book (P/B) ratio of 21.55. Compared to its 3-year average P/B ratio of 26.84, the current P/B ratio is approximately -19.72% higher. Relative to its 5-year average P/B ratio of 27.58, the current P/B ratio is about -21.88% higher. Madrigal Pharmaceuticals Inc (MDGL) has a Forward Free Cash Flow (FCF) yield of approximately -1.20%. Compared to its 3-year average FCF yield of -6.38%, the current FCF yield is approximately -81.22% lower. Relative to its 5-year average FCF yield of -9.15%, the current FCF yield is about -86.90% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MDGL competitors is 1376.47, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL.O) exhibits a P/S ratio of 9.90, which is -99.28% above the industry average. Given its robust revenue growth of 210.77%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MDGL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MDGL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MDGL currently overvalued or undervalued?

Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.90 is considered Undervalued compared with the five-year average of 17.24. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 14472.03 to 14601.33 according to relative valuation method. Compared to the current price of 444.83 USD, Madrigal Pharmaceuticals Inc is Undervalued By 96.93%.

What is Madrigal Pharmaceuticals Inc (MDGL) fair value?

MDGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 14472.03 to 14601.33 according to relative valuation method.

How does MDGL's valuation metrics compare to the industry average?

The average P/S ratio for MDGL's competitors is 1376.47, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL) exhibits a P/S ratio of 9.90, which is -99.28% above the industry average. Given its robust revenue growth of 210.77%, this premium appears sustainable.

What is the current P/B ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Mar 14 2026?

As of Mar 14 2026, Madrigal Pharmaceuticals Inc (MDGL) has a P/B ratio of 21.55. This indicates that the market values MDGL at 21.55 times its book value.

What is the current FCF Yield for Madrigal Pharmaceuticals Inc (MDGL) as of Mar 14 2026?

As of Mar 14 2026, Madrigal Pharmaceuticals Inc (MDGL) has a FCF Yield of -1.20%. This means that for every dollar of Madrigal Pharmaceuticals Inc's market capitalization, the company generates -1.20 cents in free cash flow.

What is the current Forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Mar 14 2026?

As of Mar 14 2026, Madrigal Pharmaceuticals Inc (MDGL) has a Forward P/E ratio of 726.27. This means the market is willing to pay $726.27 for every dollar of Madrigal Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Mar 14 2026?

As of Mar 14 2026, Madrigal Pharmaceuticals Inc (MDGL) has a Forward P/S ratio of 9.90. This means the market is valuing MDGL at $9.90 for every dollar of expected revenue over the next 12 months.

MDGL Valuation